NLV Partners hires Dr Liam Ratcliffe as venture partner

Dr Ratcliffe most recently served as senior vice president and development head for Pfizer Neuroscience, and also worldwide head of clinical research and development.

'During his 12 year tenure at Pfizer, Liam worked at the interfaces between drug discovery, pre-clinical development and experimental medicine,' said Dr Philippe Chambon, managing director at NLV Partners. 'These experiences have given him a deep understanding of the opportunities and risks along the clinical development axis and across therapeutic fields. This background will be a great asset as Liam works with existing and potential portfolio companies in helping them de-risk their most critical pipeline projects.'

Dr Ratcliffe began his career in the pharmaceutical industry in a medical marketing role at Roche in South Africa.

NLV Partners invests primarily in companies focused on clinical stage biopharmaceutical products, early stage medical devices and molecular diagnostics. The firm manages over $1.3bn of assets, including NLV-I, NLV-II and the healthcare technology portfolio of Sprout Group.

NLV Partners has offices in Menlo Park and New York.

Copyright © 2008 AltAssets